Oncotelic Therapeutics, Inc. (OTLC): who owns it and who trades it
As of Oct 30, 2026, OTLC insiders reported 9 purchases worth $61.3K in the last 12 months. The largest buyer was Vuong Trieu (CEO), with $60.3K.
Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, OTLC insiders reported $61.3K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Vuong Trieu | CEO | Purchase | 1.04M | $0.02 | $17.8K | Form 4 |
| Oct 28, 2026 | Vuong Trieu | CEO | Purchase | 312,000 | $0.02 | $5.8K | Form 4 |
| Jul 1, 2026 | Vuong Trieu | CEO | Purchase | 240,000 | $0.04 | $9.6K | Form 4 |
| Jun 24, 2026 | Vuong Trieu | CEO | Purchase | 115,000 | $0.05 | $5.8K | Form 4 |
| Jun 23, 2026 | Vuong Trieu | CEO | Purchase | 75,000 | $0.05 | $3.8K | Form 4 |
| Jun 22, 2026 | Vuong Trieu | CEO | Purchase | 65,000 | $0.05 | $3.2K | Form 4 |
| Jun 22, 2026 | Amit B. Shah | CFO | Purchase | 20,000 | $0.05 | $1K | Form 4 |
| Jun 17, 2026 | Vuong Trieu | CEO | Purchase | 239,759 | $0.04 | $9.6K | Form 4 |
| Jun 15, 2026 | Vuong Trieu | CEO | Purchase | 96,000 | $0.05 | $4.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Vuong Trieu | CHAIRMAN AND CEO, Director, 10% owner | $60.3K | – | Oct 29, 2026 |
| Amit B. Shah | CFO | $1K | – | Jun 22, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
OTLC short interest
Low short interest. Less than 0.1% of OTLC shares are sold short. Over the last 12 reports the number of shares short went down 12%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 99,181 OTLC shares were sold short, 0.0% of the shares outstanding, down 56.7% from the report before. At the average daily volume of 738,430 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 99,181 | 0.02% | -57% | 738,430 | 1.0 |
| Oct 15, 2026 | 229,146 | 0.05% | +1344% | 954,798 | 1.0 |
| Sep 30, 2026 | 15,874 | 0.00% | +21% | 869,558 | 1.0 |
| Sep 15, 2026 | 13,144 | 0.00% | -52% | 422,623 | 1.0 |
| Aug 31, 2026 | 27,645 | 0.01% | +172681% | 474,592 | 1.0 |
| Aug 14, 2026 | 16 | 0.00% | -100% | 322,731 | 1.0 |
| Jul 31, 2026 | 9,551 | 0.00% | -84% | 481,032 | 1.0 |
| Jul 15, 2026 | 58,489 | 0.01% | -38% | 825,988 | 1.0 |
| Jun 30, 2026 | 94,847 | 0.02% | +320% | 483,454 | 1.0 |
| Jun 15, 2026 | 22,583 | 0.01% | -27% | 388,262 | 1.0 |
| May 29, 2026 | 30,887 | 0.01% | -73% | 560,221 | 1.0 |
| May 15, 2026 | 112,539 | 0.03% | +20% | 836,907 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Oncotelic Therapeutics company events
Oncotelic Therapeutics filed 19 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 26, 2026.
- Oct 26, 2026AnnouncementSaran Saund, Chief Business Officer of Oncotelic Therapeutics Inc. made a presentation at the 22nd Drug Discovery Strategic Summit, October 21–22, 2026 at the Westin San Francisco Airport, Millbrae, California. Filing
- Oct 13, 2026AnnouncementOn October 7 and 8, 2026, representatives of Oncotelic Therapeutics Inc. presented information regarding its PDAOAI platform and hepatocellular carcinoma research at Drug Discovery 2026 in Burlingame, California. Filing
- Aug 4, 2026AgreementOncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement, with Pacific Pier Capital II, LP, and the Company issued a convertible promissory note in the aggregate gross principal amount of $178,410. Filing
- Jul 14, 2026AnnouncementOncotelic Therapeutics, Inc. presented a corporate presentation to its employees, directors and officers and advisors. Filing
- Jul 14, 2026LeadershipThe board of directors of Oncotelic Therapeutics, Inc. approved the granting of certain restricted stock units to the Company’s directors and officers and to certain employees and advisors, that are employed by the Company or affiliates of the Company, pursuant to the terms of Restricted Stock Unit… Filing
- Jun 29, 2026AgreementOncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement, with Pacific Pier Capital II, LP, and the Company issued a convertible promissory note in the aggregate gross principal amount of $178,410. Filing
- May 5, 2026DealBelow regarding the completion of the Merger is incorporated into this Item 1.01 by reference. Filing
- Apr 16, 2026AnnouncementThe Company issued a press release announcing that the Company’s Annual Results and corporate updates. Filing
- Apr 2, 2026AgreementEntry Into Material Definitive Agreement. Filing
- Mar 30, 2026AnnouncementOncotelic Therapeutics, Inc. announced that Sapu Nano, in which the Company has a minority interest, will introduce its Deciparticle ™ nanomedicine platform and its advancing clinical pipeline at the Bio-Europe Spring 2026 on March 25, 2026. Filing
- Mar 30, 2026AnnouncementOncotelic Therapeutics, Inc. announced that Sapu Nano, in which the Company has a minority interest, will present new data on evorlimus toxicology at the Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo in San Diego, California. Filing
- Jan 29, 2026AgreementOncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement, with Mast Hill Fund, LP, and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33. Filing
- Jan 26, 2026LeadershipSee Item 1.01 above Item 9.01 Financial Statements and Exhibits. Filing
- Jan 7, 2026AgreementOncotelic Therapeutics, Inc. announced entering into an amendment to an independent contractor agreements with Jefferson Capital Ventures, LLC dated August 6, 2025, for modifying the threshold of the first milestone contained within the ICA. The ICA called for Jefferson to earn certain restricted… Filing
- Jan 6, 2026AgreementOncotelic Therapeutics, Inc. entered into an amendment to an independent contractor agreements with Jefferson Capital Ventures, LLC dated August 6, 2025, for modifying the threshold of the first milestone contained within the ICA. The ICA called for Jefferson to earn certain restricted stock awards… Filing
- Jan 6, 2026AgreementSee Item 3.02 below, Item 3.02 Unregistered Sales of Equity Securities. Filing
- Dec 30, 2025AgreementSee Item 3.02 below, Item 3.02 Unregistered Sales of Equity Securities. Filing
- Dec 23, 2025AnnouncementOncotelic Therapeutics, Inc. issued a press release to announce open access to PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models (LLMs) on proprietary data. Filing
- Dec 9, 2025AgreementSee Item 3.02 below, Item 3.02 Unregistered Sales of Equity Securities. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Oncotelic Therapeutics financials
Questions about Oncotelic Therapeutics, Inc. (OTLC) stock
Are OTLC insiders buying or selling?
In the last 12 months, OTLC insiders reported 9 open-market purchases worth $61.3K and no sales. The latest trade was on Oct 29, 2026. See every trade.
What is the short interest in OTLC?
As of Oct 30, 2026, 99,181 OTLC shares were sold short, 0.0% of the shares outstanding, down 56.7% from the report before. At the average daily volume of 738,430 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.